Quick Links: Knowledge Base, Podcast, and Social
Knowledge Base — search and filter every article and podcast episode by topic, section, and keyword: kb.onhealthcare.tech
Listen to the Podcast — every article is also available as an audio episode. Free subscribers get the public episodes; paid subscribers get the full archive including subscriber-only episodes. Listen on Apple Podcasts, Spotify, or browse all episodes on the Substack Podcast page.
For paid subscribers — your subscription unlocks the entire research archive (538+ deep-dives), every paid podcast episode, and full search inside the Knowledge Base. To listen to paid episodes in Apple or Spotify, link your Substack subscription via the show settings on those platforms (instructions inside the Substack app under Subscriptions → Podcast).
For free subscribers — free posts and free podcast episodes are always public on Apple/Spotify and Substack. Upgrade any time at onhealthcare.tech/subscribe to access the paid archive and paid episodes.
Follow on Social — X · YouTube · TikTok · Instagram
The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List is the regulatory end of compounded GLP-1s from outsourcing facilities. The stated rationale is that no clinical need exists for 503B compounding when the branded products are commercially available. This episode breaks down what the proposal actually does, who it affects, and where the hard line between clinical need and economic need gets drawn.
Part I covers the 503B legal framework, the specific exclusion mechanism being used, and what the proposal means for the outsourcing facilities that built programs around compounded GLP-1 production during the shortage period. Part II examines the comment period dynamics, the litigation risk from affected parties, and the downstream effects on compounding pharmacies, telehealth prescribers, and the patients who were using compounded formulations for cost reasons rather than shortage reasons.
